Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
33 results
- D1.524 - StingReady: a safe and alternative method for controlled sting challenge tests
- D1.515 - Occupational Exposure of Patients Allergic to Hymenoptera Venom
- D1.516 - Compliance with hymenoptera venom inmunotherapy (VIT)
- D1.517 - Adverse Reactions to Insect Venom Immunotherapy in a Reference Center
- D1.518 - Patient Phenotypes in Prolonged Immunotherapy for Hymenoptera Venom
- D1.519 - Safety of ultra-rush protocols in venom immunotherapy: a systematic review and meta-analysis of Portuguese data
- D1.520 - Immunological modulation during Apis mellifera venom immunotherapy
- D1.521 - Rarer occurrence of cancer and autoimmune diseases among older patients with life-threatening allergic reactions to insect venom
- D1.522 - Efficacy of hymenoptera venom immunotherapy in Portugal: a systematic review
- D1.523 - Clinical characterization of patients with Hymenoptera venom allergy undergoing venom immunotherapy stratified by basal serum tryptase
- D1.525 - Implementation of allergen-specific immunotherapy for insect allergy
D1.526 - Epidemiologic Characteristics of Hymenoptera Venom Allergic Patients from Two Different Environmental Areas
- D1.527 - Low tryptase and combined IgE biomarkers have limited predictive value in children with severe honeybee venom anaphylaxis
D2.19 - Can Drug Provocation Be Avoided in Low-Risk Quinolone Reactions?
D2.25 - Epicutaneous responses to Bradykinin Receptor 1 and 2 agonists, Histamine, and mast cell agonists in Angiotensin Converting Enzyme Inhibitor angioedema
D2.17 - Diagnostic profitability of penicilloyl-polylysine and minor determinant mixture in urgent/preferred beta-lactam allergy studies in hospitalized patients from january 2023 to december 2025
D2.18 - Evaluating the Penicillin Allergy Diagnosis Process with Real-Life Data
D2.20 - Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing
D2.21 - The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity
D2.26 - Applying a phenotype-driven diagnostic algorithm to suspected hypersensitivity reactions to biologicals: a real-world experience
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download